{"id":"https://openalex.org/W2607278979","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.e19065","title":"Phase I study of rilotumumab (AMG 102), an HGF inhibitor, and erlotinib in patients with advanced non-small cell lung cancer (NSCLC).","display_name":"Phase I study of rilotumumab (AMG 102), an HGF inhibitor, and erlotinib in patients with advanced non-small cell lung cancer (NSCLC).","publication_year":2014,"publication_date":"2014-05-20","ids":{"openalex":"https://openalex.org/W2607278979","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.e19065","mag":"2607278979"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2014.32.15_suppl.e19065","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.e19065","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2014.32.15_suppl.e19065","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103010258","display_name":"Phu N. Tran","orcid":"https://orcid.org/0000-0002-8118-2381","observed_orcids":["https://orcid.org/0000-0002-8118-2381"]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Phu Tran","raw_affiliation_strings":["University of Pittsburgh Cancer Institute, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh Cancer Institute, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017526826","display_name":"William E. Gooding","orcid":"https://orcid.org/0000-0001-9070-3559","observed_orcids":["https://orcid.org/0000-0001-9070-3559"]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William E. Gooding","raw_affiliation_strings":["University of Pittsburgh Cancer Institute, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh Cancer Institute, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082389042","display_name":"Liza Cosca Villaruz","orcid":"https://orcid.org/0000-0001-7456-523X","observed_orcids":["https://orcid.org/0000-0001-7456-523X"]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Liza Cosca Villaruz","raw_affiliation_strings":["University of Pittsburgh Cancer Institute, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh Cancer Institute, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043862738","display_name":"Timothy Francis Burns","orcid":"https://orcid.org/0000-0002-8685-3762","observed_orcids":["https://orcid.org/0000-0002-8685-3762"]},"institutions":[{"id":"https://openalex.org/I170201317","display_name":"University of Pittsburgh","ror":"https://ror.org/01an3r305","country_code":"US","type":"education","lineage":["https://openalex.org/I170201317"]},{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Timothy Francis Burns","raw_affiliation_strings":["University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA","institution_ids":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078629724","display_name":"Mark A. Socinski","orcid":"https://orcid.org/0000-0003-2915-9325","observed_orcids":["https://orcid.org/0000-0003-2915-9325","https://orcid.org/0000-0002-8213-0137"]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark A. Socinski","raw_affiliation_strings":["University of Pittsburgh Cancer Institute, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh Cancer Institute, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5020955148","display_name":"Ahmad A. Tarhini","orcid":"https://orcid.org/0000-0002-3193-9702","observed_orcids":["https://orcid.org/0000-0002-3193-9702"]},"institutions":[{"id":"https://openalex.org/I4210134769","display_name":"University of Pittsburgh Medical Center","ror":"https://ror.org/04ehecz88","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210098814","https://openalex.org/I4210134769"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ahmad A. Tarhini","raw_affiliation_strings":["University of Pittsburgh Medical Center, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh Medical Center, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210134769"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"32","issue":"15_suppl","first_page":"e19065","last_page":"e19065"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rilotumumab","display_name":"rilotumumab","score":0.996999979019165},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.902999997138977},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.8709999918937683},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6790000200271606},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8399999737739563},{"id":"https://openalex.org/keywords/recommended-phase-ii-dose","display_name":"recommended phase 2 dose","score":0.8109999895095825},{"id":"https://openalex.org/keywords/egfr-tki-resistance","display_name":"EGFR tyrosine kinase inhibitor resistance","score":0.6800000071525574},{"id":"https://openalex.org/keywords/egfr-l858r-mutation","display_name":"L858R mutation","score":0.7429999709129333},{"id":"https://openalex.org/keywords/lung-squamous-cell-carcinoma","display_name":"lung squamous cell carcinoma","score":0.6769999861717224},{"id":"https://openalex.org/keywords/adenocarcinoma","display_name":"adenocarcinoma","score":0.9449999928474426},{"id":"https://openalex.org/keywords/dose-de-escalation","display_name":"dose de-escalation","score":0.699999988079071},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.4300000071525574}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9218511581420898},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.8498280048370361},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.6914194226264954},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6338663101196289},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5626998543739319},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.5502873659133911},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.5231783986091614},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.43721845746040344}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2014.32.15_suppl.e19065","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.e19065","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2014.32.15_suppl.e19065","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2603396766","https://openalex.org/W2610255173","https://openalex.org/W2759566549","https://openalex.org/W2981031729","https://openalex.org/W4220814318","https://openalex.org/W2611153764","https://openalex.org/W2769653645","https://openalex.org/W2014230197","https://openalex.org/W2518987508","https://openalex.org/W2978897255"],"abstract_inverted_index":{"e19065":[0],"Background:":[1],"MET":[2,11,50],"is":[3,31,356],"frequently":[4],"overexpressed":[5],"in":[6,72,354],"NSCLC":[7,186,219,355],"and":[8,12,45,62,70,97,121,210,256,290,310,341],"amplification":[9],"of":[10,21,48,68,159,207,321],"its":[13],"ligand,":[14],"hepatic":[15],"growth":[16,25],"factor":[17,26],"(HGF),":[18],"are":[19],"mechanisms":[20],"resistance":[22],"to":[23,40,58,116,126,138],"epidermal":[24],"receptor":[27],"(EGFR)":[28],"inhibitors.":[29],"Rilotumumab":[30],"a":[32,117,150],"fully":[33],"human":[34],"monoclonal":[35],"antibody":[36],"(IgG2)":[37],"that":[38,237],"binds":[39],"HGF":[41],"with":[42,74,87,149,188,218,300],"high":[43],"affinity":[44],"inhibits":[46],"activation":[47],"the":[49,60,122,142,146,157,160,170,174,319,324,329,348],"pathway.":[51],"This":[52],"phase":[53,64,351],"I":[54],"trial":[55,134,359],"was":[56,85,110,125,136,141,347],"conducted":[57],"evaluate":[59],"safety":[61],"recommended":[63],"2":[65,245,311],"dose":[66,82,108,124,144,147,178,331],"(RP2D)":[67],"rilotumumab":[69,88],"erlotinib":[71,98,342],"pts":[73,187,217,294,327],"recurrent":[75],"or":[76,193],"progressive,":[77],"advanced":[78],"NSCLC.":[79],"Methods:":[80],"A":[81,350],"de-escalation":[83,109,163],"design":[84,120],"adopted":[86],"starting":[89],"at":[90,99],"15":[91,335],"mg/kg":[92,336],"IV":[93,185,337],"every":[94,205,212,338],"3":[95,208,235,306,339],"weeks":[96,209,340],"150":[100,343],"mg":[101,344],"PO":[102,345],"daily":[103],"(dose":[104],"level":[105,179,332],"0).":[106],"If":[107],"needed":[111],"it":[112],"would":[113,176],"proceed":[114],"according":[115],"Narayana":[118],"k-in-a-row":[119],"selected":[123],"be":[127,177],"estimated":[128],"by":[129,315],"isotonic":[130],"regression.":[131],"For":[132],"this":[133],"k":[135],"set":[137],"3.":[139],"RP2D":[140,175],"maximum":[143],"below":[145],"associated":[148],"25%":[151],"dose-limiting":[152],"toxicity":[153],"(DLT)":[154],"rate.":[155],"In":[156,318],"absence":[158,320],"need":[161],"for":[162,242],"per":[164],"protocol":[165],"specified":[166],"decision":[167],"rules":[168],"among":[169,323],"first":[171,325],"8":[172,326],"patients":[173],"0.":[180],"Enrollment":[181],"criteria":[182,241],"included":[183,262],"stage":[184],"ECOG":[189],"performance":[190],"status":[191],"1":[192,260],"less":[194],"who":[195],"failed":[196],"1-2":[197],"prior":[198],"chemotherapy":[199],"regimens.":[200],"Pts":[201],"were":[202,225,228,247],"assessed":[203],"clinically":[204],"cycle":[206],"radiologically":[211],"6":[213],"weeks.":[214],"Results:":[215],"Eight":[216],"(4":[220],"squamous":[221],"cell;":[222],"4":[223],"adenocarcinoma)":[224],"enrolled.":[226],"There":[227],"no":[229],"DLTs.":[230],"One":[231],"pt":[232],"had":[233,295,307,312],"Grade":[234,244,259],"rash":[236,248,263],"did":[238],"not":[239],"meet":[240],"DLT.":[243],"toxicities":[246,261],"(n=4),":[249],"diarrhea":[250,265],"(1),":[251,253,255,272,275,277,280,284,286,289],"fatigue":[252,271],"hypertension":[254],"edema":[257,267],"(1).":[258,292],"(4),":[264],"(2),":[266,268,270],"paronychia":[269],"abdominal":[273],"pain":[274],"lymphopenia":[276],"elevated":[278,281],"bilirubin":[279],"alkaline":[282],"phosphatase":[283],"proteinuria":[285],"muscle":[287],"spasm":[288],"alopecia":[291],"Three":[293],"partial":[296],"tumor":[297],"response":[298],"(one":[299],"EGFR":[301],"p.L858R":[302],"exon":[303],"21":[304],"mutation),":[305],"stable":[308],"disease,":[309],"progressive":[313],"disease":[314],"RECIST.":[316],"Conclusions:":[317],"DLTs":[322],"on":[328],"study,":[330],"0":[333],"(Rilotumumab":[334],"daily)":[346],"RP2D.":[349],"II":[352],"study":[353],"ongoing.":[357],"Clinical":[358],"information:":[360],"NCT01233687.":[361]},"counts_by_year":[{"year":2018,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":1}],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2017-04-28T00:00:00"}